[Federal Register Volume 62, Number 161 (Wednesday, August 20, 1997)]
[Notices]
[Pages 44285-44286]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-22033]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Biomedical Uses of 
Topoisomerase I Inhibitors Including Camptothecin and Derivatives for 
Retroviral Applications Including Human Immunodeficiency Virus (HIV)

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
a domestic exclusive license to practice the inventions embodied in the 
patents and patent applications referred to below to Virologix 
Corporation of New York, New York. The patent rights in these 
inventions have been assigned to the government of the United States of 
America. The patents and patent applications to be licensed are:


[[Page 44286]]



``METHOD OF TREATING RETROVIRAL INFECTIONS IN MAMMALS''

U.S. Patent Application Serial No. 07/520,456, filed May 8, 1990, 
which issued on June 6, 1995 as U.S. Patent No. 5,422,344; and
U.S. Patent Application Serial No. 08/397,936, filed March 3, 1995, 
which issued on April 22, 1997 as U.S. Patent No. 5,622,959.

DATES: Only written comments and/or applications for a license which 
are received by NIH on or before October 20, 1997 will be considered.

ADDRESSES: Requests for a copy of these patents, inquiries, comments, 
and other materials relating to the contemplated license should be 
directed to: J. Peter Kim, Technology Licensing Specialist, Office of 
Technology Transfer, National Institutes of Health, 6011 Executive 
Boulevard, Suite 325, Rockville, Maryland 20852-3804; Telephone: (301) 
496-7056, ext. 264; Facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: The present invention relates to a method of 
treating retroviral infections in mammals via the use of an effective 
amount of topoisomerase I inhibitor such as camptothecin (CPT) and 
similar compounds which act as inhibitors of retrovial topoisomerase I, 
blocking both the initiation of retroviral infection and replication in 
target cells. As a consequence of this mechanism of action, use of such 
inhibitors provides a potential means of reducing or eliminating 
retroviral infections and their deleterious consequences through both 
human and veterinary medicine applications.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within sixty 
(60) days from the date of this published notice, NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7.
    Applications for a license filed in response to this notice will be 
treated as objections to the grant of the contemplated license. 
Comments and objections submitted in response to this notice will not 
be made available for public inspection, and, to the extent permitted 
by law, will not be released under the Freedom of Information Act, 5 
U.S.C. 552. Copies of the subject issued patents are available upon 
request.

    Dated: August 4, 1997.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-22033 Filed 8-19-97; 8:45 am]
BILLING CODE 4140-01-M